Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma
Metrics: PDF 1610 views | HTML 2080 views | ?
Tianling Wei1, Edyta Biskup1, Lise Mette Rahbek Gjerdrum2, Omid Niazi1, Niels Ødum3,4, Robert Gniadecki1,4
1Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark
2Department of Pathology, Zealand University Hospital, Køge, Denmark
3Institute of Medical Microbiology and Immunology, University of Copenhagen, Copenhagen, Denmark
4Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
Tianling Wei, email: [email protected]
Keywords: ubiquitin-specific protease 2, cutaneous T-cell lymphoma, PUVA
Received: October 26, 2015 Accepted: June 09, 2016 Published: June 24, 2016
Treatment of advanced cutaneous T-cell lymphomas (CTCL) is challenging because they are resistant to conventional chemotherapy. USP2 has been shown to promote resistance to chemotherapeutic agents in several cancer models.
We show here USP2 is expressed in quiescent and activated T-cells and its expression is 50% lower in CTCL cell lines (MyLa2000, SeAx and Hut-78) than in normal T-cells. USP2 is expressed in neoplastic cells in early, plaque-stage mycosis fungoides (MF) and is downregulated in advanced tumor stages. Upon treatment with psoralen with UVA (PUVA) or a p53 activator, nutlin3a, USP2 expression is significantly increased in MyLa2000 (p53wt/wt), but not in SeAx (p53mut) or Hut-78 (p53-/-). USP2 knockdown decreases MyLa2000 cell viability after PUVA by 50% but not Hut-78, suggesting that the function of USP2 in CTCL cells is p53-dependent. Furthermore, USP2 knockdown results in a decreased Mdm2 expression and upregulation of p53. Taken together, our findings suggest that USP2 stabilizes Mdm2 which antagonizes pro-apoptotic activity of p53 and possibly contributes to therapeutic resistance in CTCL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.